Effect of multispecies probiotics on autism symptoms: protocol for a randomized controlled trial (PROBAUT) Authors: Maja Kotowska-Bąbol, Łukasz Konowałek, Hania Szajewska, Jan Łukasik Published: 2025 ABSTRACT AbstractIntroductionAutism spectrum disorder (ASD) affects millions of children worldwide, negatively impacting the daily functioning and quality of life of patients and their families. New therapeutic approaches for ASD are being investigated. Probiotics have shown promise in modulating gut microbiota and ameliorating ASD symptoms. We aim to evaluate the impact of a 12-week multispecies probiotic supplementation on the severity of core autism symptoms in children with ASD.Methods and analysisThis study is a randomized, double-blind, placebo-controlled clinical trial. One hundred and 10 children aged 7 to 15 years diagnosed with ASD will be randomly assigned in a 1:1 ratio to receive either a probiotic mixture or a placebo for 12 weeks. The probiotic mixture contains 5 × 109 colony-forming units per dose of Bacillus subtilis W20, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Levilactobacillus brevis W63, Lacticaseibacillus rhamnosus W140, Lactococcus lactis W19, and Propionibacterium freudenreichii W200. The primary outcome will be the assessment of core autism symptoms using the Autism Symptom Rating Scales (ASRS). The secondary outcomes will include the quality of life, evaluations of sleep impairments, parental stress levels, gastrointestinal symptoms, and urinary p-cresol levels. These outcomes will be assessed twice: at baseline and after 12 weeks of intervention.Ethics and disseminationThe study has received approval from the Ethics Committee of the Medical University of Warsaw. Results will be submitted to a peer-reviewed journal and presented at national and international scientific meetings.Trial registrationNCT06448767. Registered on 3 June 2024Protocol versionVersion 2, 27 of October 2025Supplementary InformationThe online version contains supplementary material available at 10.1186/s13063-025-09373-w.Keywords: Autism spectrum disorder, Probiotics, Quality of life Introduction Autism spectrum disorder (ASD) is a complex neurodevelopmental condition characterized by impairments in social interaction and communication and the presence of repetitive, restricted behaviors [1]. The incidence of ASD has been rising annually, with the latest data from the Centers for Disease Control and Prevention (CDC) indicating the prevalence of 1 in 36 8-year-old children and reporting that boys are 3.8 times more likely to be affected than girls [2]. The etiopathogenesis is not fully understood; however, it is hypothesized that genetic predisposition combined with external and environmental factors plays a role in the pathogenesis of ASD [3]. Currently, significant research efforts are directed toward the intestinal microbiota and the “gut-brain axis” and its impact on the course of neurodevelopmental disorders. This bidirectional, neurohumoral communication system transmits information through the enteric nervous system and the vagus nerve to the central nervous system, affecting cognitive, behavioral, and psychological functions [4]. It is hypothesized that alterations in the composition of intestinal microbiota and disturbances in the gut-brain axis could play a role in the pathogenesis of ASD, and therefore, targeting the gut microbiota could emerge as a novel treatment approach [5]. Currently, the recommended treatment for children with ASD includes early intervention through behavioral, occupational, and speech therapies. Pharmacological interventions are used to manage associated symptoms like irritability, anxiety, and hyperactivity. Recently, the US Food and Drug Administration (FDA) has approved two antipsychotic medications, risperidone and aripiprazole, for treating irritability in children with ASD [6, 7]. Dietary interventions, including gluten-free, casein-free, and ketogenic diets, are also explored for their potential benefits [8–11]. Another branch of research is focused on the possibility of modifying the composition and function of gut microbiota through the use of probiotics. Probiotics are defined as a “live microorganisms that, when administered in adequate amounts, confer a health benefit on the host” [12]. Probiotics are hypothesized to modulate ASD symptoms by restoring gut microbial balance and influencing gut–brain communication [13]. Experimental studies indicate that certain strains can affect neural circuits involved in social behavior via the vagus nerve and oxytocin-dopaminergic signaling pathways [14, 15]. To our knowledge, 12 different studies have investigated the effects of probiotic supplementation on autism symptoms in children, yielding inconsistent and mixed findings [16–27]. The studies were conducted on various groups ranging in age from 18 months to 16 years; the intervention period varied from 28 days to 6 months, and multiple different endpoints were assessed. A recent study conducted by Mazzone et al. presented promising results indicating that 6 months of probiotic supplementation improved social functioning in children with autism [19]. Nonetheless, this supplementation did not lead to an improvement in overall autism severity or repetitive behaviors. Similarly, another study by Liu et al. reported encouraging findings, demonstrating that supplementation with Lactobacillus plantarum PS128 for 28 days alleviated oppositional and defiance behaviors and attention-deficit/hyperactivity disorder symptoms [25]. Systematic reviews of randomized clinical trials (RCTs) published so far do not confirm the positive effect of probiotics on ASD symptoms and quality of life in children [28, 29]. This lack of confirmation is likely due to the paucity of data and poor methodology of the studies, including small sample sizes, short intervention periods, the variety of outcomes assessed, and a lack of agreement on the probiotic strain and dosage. Caring for children with ASD can be emotionally, physically, and financially exhausting. Studies have shown that mothers of children with ASD exhibit higher stress levels than mothers of healthy controls or children with conditions such as Down syndrome, fragile X syndrome, or cerebral palsy [30, 31]. Families burdened with ASD are exposed to higher levels of family problems and stress than those with children suffering from Down syndrome, attention-deficit hyperactivity disorder (ADHD), or cystic fibrosis [32–34]. Therefore, measuring the quality of life (QoL) of parents of children with ASD could be a good indicator of the family’s overall well-being and indirectly reflect the condition of the child with ASD. There is a need for well-designed RCTs evaluating the effects of probiotics in patients with autism spectrum disorder, as the data published to date are limited and inconclusive. Methods and analysis Aim We aim to investigate whether a 12-week therapy with a multispecies probiotic improves core autism symptoms of children with ASD. Trial design This study is a randomized, double-blind, placebo-controlled, parallel-group superiority clinical trial with an allocation ratio of 1:1. The trial was registered in the ClinicalTrials.gov database, registration number NCT06448767. Recruitment and study setting Recruitment will take place at the Autism Outpatient Clinic, the Department of Psychiatry, Children’s Clinical Hospital, the Medical University of Warsaw, Poland, and at a cooperating special education school for children with ASD in Aleksandrów Łódzki, Poland. The intervention will be delivered at participants’ homes. Outcome assessments, including clinical evaluations and questionnaire completion, will be conducted during follow-up visits at the Autism Outpatient Clinic in Warsaw or at the cooperating school in Aleksandrów Łódzki. Physicians, psychologists, and teachers involved in the care of children with ASD will inform eligible families about the study and provide them with study information materials. Recruitment posters and leaflets will be distributed to raise awareness about the study. The principal investigator (PI) will be present in person for approximately 4 days each month in the ASD mental health clinic of the Medical University of Warsaw, to directly inform the patients and their parents/caregivers about the study. Twice a year, information meetings for parents will be organized in the school for children with ASD in Aleksandrów Łódzki. In case of an unsatisfactory recruitment rate, contact with additional schools for children with ASD located in Mazowieckie Voivodeship, Poland, will be made to launch recruitment in additional sites. The recruitment period is planned to last approximately 2 years from the start of the trial. Eligibility criteria Inclusion criteria Diagnosis of ASD according to the Diagnostic and Statistical Manual of Mental Disorders, the fifth edition (DSM-5) or International Classification of Diseases, Tenth Revision (ICD-10) Diagnosis of ASD according to the Diagnostic and Statistical Manual of Mental Disorders, the fifth edition (DSM-5) or International Classification of Diseases, Tenth Revision (ICD-10) Males and females between 7 and 15 years old Males and females between 7 and 15 years old Children either not taking any medication or receiving the same medication for the last 2 months Children either not taking any medication or receiving the same medication for the last 2 months Patients, or their parents/caregivers, are willing to provide written informed consent, proceed with nutritional supplements throughout the 3-month trial, refrain from starting any kind of special diet for the duration of the study, and complete the questionnaires at two time points during the study. Patients, or their parents/caregivers, are willing to provide written informed consent, proceed with nutritional supplements throughout the 3-month trial, refrain from starting any kind of special diet for the duration of the study, and complete the questionnaires at two time points during the study. Exclusion criteria Use of antibiotics in the previous 2 months before enrolling (excluding topical antibiotics) Use of antibiotics in the previous 2 months before enrolling (excluding topical antibiotics) Use of probiotics or synbiotics within the previous 2 months Use of probiotics or synbiotics within the previous 2 months History of intolerance or allergy to probiotics, synbiotics, or any other study product component. History of intolerance or allergy to probiotics, synbiotics, or any other study product component. Surgery with bowel resection or short bowel syndrome Surgery with bowel resection or short bowel syndrome Children with severe immunodeficiency Children with severe immunodeficiency Intervention The probiotic mixture selected for the study is in the form of a white to ivory-colored powder. It has a concentration of 5 × 109 colony-forming units (CFU) per dose (2 g). The mixture contains Bacillus subtilis W20, Bifidobacterium infantis W17, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Levilactobacillus brevis W63, Lacticaseibacillus rhamnosus W140, Lactococcus lactis W19, and Propionibacterium freudenreichii W200. The bacterial strains are evenly distributed across the total daily dose of 5 × 10⁹ CFU. The product must be stored in a dry place under stable ambient conditions (between 15 and 25°, outside the refrigerator) and must be protected from extremes of light and humidity. The placebo will be identical in taste, appearance, and smell and will not contain bacterial strains. The probiotic preparation and placebo will be stored in identical packages. Patients will be asked to take the product orally — either probiotic or placebo — once daily for 12 weeks. The product should be taken on an empty stomach, in the morning before breakfast, or in the evening at bedtime. Two grams of either powder needs to be dissolved in 100 mL of water, milk, yoghurt, other dairy products, or dairy substitutes, and not in fruit juices or warm liquids. Randomization and blinding A computer-generated randomization list, prepared by a person not involved in the trial, will be used to allocate participants to study groups in variable blocks of four, with an allocation ratio of 1:1. The randomization list will be generated using an online tool provided by Sealed Envelope Ltd. [35]. Consecutive randomization numbers (1, 2, 3, etc.) will be assigned to participants upon enrollment. Each number corresponds to a number on the randomization list as well as a number on the unique box with study product. Separate sealed envelopes containing the allocation of each participant will be handed to the study supervisor and stored in a closed locker at the study site, ensuring that if a medical emergency occurs for which treatment allocation knowledge is needed, the code can be broken at any time. The study will be double-blinded, i.e., trial participants and their parents or caregivers, and investigators will not be aware of the allocation. Enrollment of participants and assignment of consecutive randomization numbers will be performed by the PI. Unblinding To ensure the safety of study participants, emergency unblinding of participants of interest should be performed yet only in exceptional situations when knowledge of the actual treatment is essential for further patient management. Partial unblinding of all study participants (i.e., allocation to group “A” or “B”) will be performed after completion of the 3-month trial period of the last participant and final evaluation of the outcomes. Complete unblinding (i.e., allocation to probiotic or placebo group) will be performed after the full analysis of the data. Concomitant therapies Participants are allowed to continue taking their current medications or other therapies they were receiving before the study began (behavioral therapy, speech therapy, occupational therapy, or educational support). Participants will be instructed not to introduce any new diet or dietary supplements, including pre-, pro-, or synbiotics, unless medically necessary (e.g., a new diagnosis of celiac disease requiring a gluten-free diet). Any participant who starts a long-term treatment with a new drug, systemic antibiotic, or antifungal treatment, or introduces a new diet or dietary supplement during the trial, will be excluded from the per-protocol analysis. Discontinuation Participants will discontinue their participation in the study in the following situations: Withdrawal of consent Withdrawal of consent Further participation is a health risk for the subject, at the investigator’s discretion. Further participation is a health risk for the subject, at the investigator’s discretion. Pregnancy of the participant Pregnancy of the participant The study is prematurely terminated or suspended. The study is prematurely terminated or suspended. Participants who choose to discontinue the intervention may, if willing, remain in the trial for follow-up assessments according to the study schedule. The data of these patients will be analyzed according to the intention-to-treat principle. In the event of premature withdrawal (after randomization), all efforts will be made to contact the participant and ensure that all evaluations are carried out, documented, and reported in the study case report form (CRF) unless the participant refuses to undergo these procedures. In that case, withdrawal of the participant’s consent will have to be documented in the source documents and reported in the study case report form (CRF). For participants who discontinue the study due to the occurrence of adverse events that are, according to the investigator, potentially related to the study product or the study procedures, follow-up will take place until the adverse event has ended or until a stable clinical situation has been reached, with findings being recorded in the medical records as well as in the CRF. Monitoring adherence To ensure adherence, e-mails reminding patients of the importance of following the study protocol will be sent to all study participants every 3 weeks. The email will include a reminder to take the study product once daily, a notification that there will be a counting of unused product packages at the final visit, and provide a link to an online questionnaire where patients will be able to report possible adverse reactions. In addition, participants’ parents or caregivers will be contacted by phone every 3 weeks to discuss study progress and confirm regular intake of the study product. During these calls, they will also be asked about any new medications, dose changes, dietary modifications, or initiation of behavioral therapies. Outcomes Primary outcome The Autism Spectrum Rating Scales (ASRS) — the difference between intervention and placebo groups in change from baseline to 3 months after treatment The Autism Spectrum Rating Scales (ASRS) — the difference between intervention and placebo groups in change from baseline to 3 months after treatment The Autism Spectrum Rating Scales (ASRS) is a standardized, validated tool used to evaluate the severity of ASD symptoms and to monitor the effects of treatment [36]. The questionnaire demonstrated high levels of internal consistency, and test–retest values indicated excellent reliability. It is intended for children aged 2 to 18 years of age. The questionnaire is available for preschoolers (2–5 years) or elementary and high school students (6–18 years) in forms that can be completed by parents/caregivers or by teachers, either online or in a paper-and-pencil form. The full version of the questionnaire, dedicated to the 6- to 18-year age group, consists of 71 questions covering 7 domains: peer socialization, adult socialization, social/emotional reciprocity, atypical language, behavioral rigidity, stereotypy, sensory sensitivity, and attention/self-regulation. Using a 5-point Likert scale, the respondent indicates how often such behaviors are observed in the child. It takes approximately 15 min to fill out the survey. Secondary outcomes The Quality of Life in Autism Part A (QoLA-A) — the difference between intervention and placebo groups in change from baseline to 3 months after treatment The Quality of Life in Autism Part A (QoLA-A) — the difference between intervention and placebo groups in change from baseline to 3 months after treatment This questionnaire was developed to measure the quality of life of parents of children with ASD between the ages of 2 and 18 years [37]. The original English version, consisting of two parts, was adapted into Polish and validated on the Polish population [38]. However, since the validation study showed an unsatisfactory level of reliability of part B of the questionnaire, only part A will be administered. Part A is a series of 28 questions to assess parents’ overall perception of their quality of life. Responses are measured using a 5-point Likert scale, ranging from 1 (not very much) to 5 (very much). Part A can be scored between 28 and 140, with higher scores indicating higher quality of life. The Parenting Stress Index-4 (PSI-4)/Stress Index for Parents of Adolescents (SIPA)Depending on the age of the participants, the intensity of parental stress will be measured using the PSI-4 or SIPA questionnaire. The PSI-4 questionnaire is dedicated for children between the ages of 0 to 10 years, while SIPA is designed for adolescents between 11 to 17 years. The PSI-4 is a caregiver-reported questionnaire that consists of 120 items and reflects three domains: child domain, parent domain, and Life Stress Scale. Responses are given on a 5-point Likert scale where “1” means “absolutely disagree” and “5” indicates “absolutely agree.” For the Life Stress Scale, the caregiver provides answers on a dichotomous “yes/no” scale. Higher scores indicate greater severity of stress experienced by the parent. The Polish version of the questionnaire was validated and published by Niedziela et al. [39]. The SIPA questionnaire consists of 112 items and takes approximately 20 min to complete [40]. It evaluates three main domains: the adolescent domain, the parent domain, and the parent-adolescent relationship domain. Parents provide answers using a 5-point Likert scale. The Polish version of the questionnaire was validated and published by Niedziela et al. [41]. The Parenting Stress Index-4 (PSI-4)/Stress Index for Parents of Adolescents (SIPA)Depending on the age of the participants, the intensity of parental stress will be measured using the PSI-4 or SIPA questionnaire. The PSI-4 questionnaire is dedicated for children between the ages of 0 to 10 years, while SIPA is designed for adolescents between 11 to 17 years. The PSI-4 is a caregiver-reported questionnaire that consists of 120 items and reflects three domains: child domain, parent domain, and Life Stress Scale. Responses are given on a 5-point Likert scale where “1” means “absolutely disagree” and “5” indicates “absolutely agree.” For the Life Stress Scale, the caregiver provides answers on a dichotomous “yes/no” scale. Higher scores indicate greater severity of stress experienced by the parent. The Polish version of the questionnaire was validated and published by Niedziela et al. [39]. The SIPA questionnaire consists of 112 items and takes approximately 20 min to complete [40]. It evaluates three main domains: the adolescent domain, the parent domain, and the parent-adolescent relationship domain. Parents provide answers using a 5-point Likert scale. The Polish version of the questionnaire was validated and published by Niedziela et al. [41]. Depending on the age of the participants, the intensity of parental stress will be measured using the PSI-4 or SIPA questionnaire. The PSI-4 questionnaire is dedicated for children between the ages of 0 to 10 years, while SIPA is designed for adolescents between 11 to 17 years. The PSI-4 is a caregiver-reported questionnaire that consists of 120 items and reflects three domains: child domain, parent domain, and Life Stress Scale. Responses are given on a 5-point Likert scale where “1” means “absolutely disagree” and “5” indicates “absolutely agree.” For the Life Stress Scale, the caregiver provides answers on a dichotomous “yes/no” scale. Higher scores indicate greater severity of stress experienced by the parent. The Polish version of the questionnaire was validated and published by Niedziela et al. [39]. The SIPA questionnaire consists of 112 items and takes approximately 20 min to complete [40]. It evaluates three main domains: the adolescent domain, the parent domain, and the parent-adolescent relationship domain. Parents provide answers using a 5-point Likert scale. The Polish version of the questionnaire was validated and published by Niedziela et al. [41]. Depending on the age of the participants, the intensity of parental stress will be measured using the PSI-4 or SIPA questionnaire. The PSI-4 questionnaire is dedicated for children between the ages of 0 to 10 years, while SIPA is designed for adolescents between 11 to 17 years. The PSI-4 is a caregiver-reported questionnaire that consists of 120 items and reflects three domains: child domain, parent domain, and Life Stress Scale. Responses are given on a 5-point Likert scale where “1” means “absolutely disagree” and “5” indicates “absolutely agree.” For the Life Stress Scale, the caregiver provides answers on a dichotomous “yes/no” scale. Higher scores indicate greater severity of stress experienced by the parent. The Polish version of the questionnaire was validated and published by Niedziela et al. [39]. The SIPA questionnaire consists of 112 items and takes approximately 20 min to complete [40]. It evaluates three main domains: the adolescent domain, the parent domain, and the parent-adolescent relationship domain. Parents provide answers using a 5-point Likert scale. The Polish version of the questionnaire was validated and published by Niedziela et al. [41]. Children Sleep Habit Questionnaire-Abbreviated (CSHQ-A)The CSHQ-A is a parent-reported scale used to detect sleep disturbances in children. It consists of 22 questions and retrospectively assesses the child’s sleep quality status in the preceding week. It assesses disorders in four domains: (1) Bedtime, (2) sleep behavior, (3) waking during the night, and (4) morning wake up. Children Sleep Habit Questionnaire-Abbreviated (CSHQ-A)The CSHQ-A is a parent-reported scale used to detect sleep disturbances in children. It consists of 22 questions and retrospectively assesses the child’s sleep quality status in the preceding week. It assesses disorders in four domains: (1) Bedtime, (2) sleep behavior, (3) waking during the night, and (4) morning wake up. The CSHQ-A is a parent-reported scale used to detect sleep disturbances in children. It consists of 22 questions and retrospectively assesses the child’s sleep quality status in the preceding week. It assesses disorders in four domains: (1) Bedtime, (2) sleep behavior, (3) waking during the night, and (4) morning wake up. The CSHQ-A is a parent-reported scale used to detect sleep disturbances in children. It consists of 22 questions and retrospectively assesses the child’s sleep quality status in the preceding week. It assesses disorders in four domains: (1) Bedtime, (2) sleep behavior, (3) waking during the night, and (4) morning wake up. Gastrointestinal Symptom Rating Scale (GSRS)The GSRS is a 15-item, parent-reported assessment of a child’s gastrointestinal complaints: constipation, diarrhea, average stool consistency, stool smell, flatulence, and abdominal pain [42]. The response is provided on a 7-point Likert scale where 1 means “the absence of symptoms” and 7 means “very troublesome symptoms.” Gastrointestinal Symptom Rating Scale (GSRS)The GSRS is a 15-item, parent-reported assessment of a child’s gastrointestinal complaints: constipation, diarrhea, average stool consistency, stool smell, flatulence, and abdominal pain [42]. The response is provided on a 7-point Likert scale where 1 means “the absence of symptoms” and 7 means “very troublesome symptoms.” The GSRS is a 15-item, parent-reported assessment of a child’s gastrointestinal complaints: constipation, diarrhea, average stool consistency, stool smell, flatulence, and abdominal pain [42]. The response is provided on a 7-point Likert scale where 1 means “the absence of symptoms” and 7 means “very troublesome symptoms.” The GSRS is a 15-item, parent-reported assessment of a child’s gastrointestinal complaints: constipation, diarrhea, average stool consistency, stool smell, flatulence, and abdominal pain [42]. The response is provided on a 7-point Likert scale where 1 means “the absence of symptoms” and 7 means “very troublesome symptoms.” P-cresol levels in urine samplesIntestinal microbiota disturbances can be reflected in body fluids such as stool or urine. Detection of bacterial metabolites in urine is a noninvasive measurement, providing a good overview of the state of the gut microbiota. P-cresol (4-methylphenol) is an organic, aromatic compound, a bacterial metabolite, and one of the metabolites of tyrosine and phenylalanine metabolism [43]. It is converted to 4-hydroxyphenyl-acetic acid by gut microbiota and then decarboxylated to p-cresol. It is hypothesized that p-cresol may contribute to worsening the severity of ASD symptoms [44]. Urine samples will be stored at −20 °C for up to 1 week and then stored at −80 °C until processing. P-cresol levels in urine samplesIntestinal microbiota disturbances can be reflected in body fluids such as stool or urine. Detection of bacterial metabolites in urine is a noninvasive measurement, providing a good overview of the state of the gut microbiota. P-cresol (4-methylphenol) is an organic, aromatic compound, a bacterial metabolite, and one of the metabolites of tyrosine and phenylalanine metabolism [43]. It is converted to 4-hydroxyphenyl-acetic acid by gut microbiota and then decarboxylated to p-cresol. It is hypothesized that p-cresol may contribute to worsening the severity of ASD symptoms [44]. Urine samples will be stored at −20 °C for up to 1 week and then stored at −80 °C until processing. Intestinal microbiota disturbances can be reflected in body fluids such as stool or urine. Detection of bacterial metabolites in urine is a noninvasive measurement, providing a good overview of the state of the gut microbiota. P-cresol (4-methylphenol) is an organic, aromatic compound, a bacterial metabolite, and one of the metabolites of tyrosine and phenylalanine metabolism [43]. It is converted to 4-hydroxyphenyl-acetic acid by gut microbiota and then decarboxylated to p-cresol. It is hypothesized that p-cresol may contribute to worsening the severity of ASD symptoms [44]. Urine samples will be stored at −20 °C for up to 1 week and then stored at −80 °C until processing. Intestinal microbiota disturbances can be reflected in body fluids such as stool or urine. Detection of bacterial metabolites in urine is a noninvasive measurement, providing a good overview of the state of the gut microbiota. P-cresol (4-methylphenol) is an organic, aromatic compound, a bacterial metabolite, and one of the metabolites of tyrosine and phenylalanine metabolism [43]. It is converted to 4-hydroxyphenyl-acetic acid by gut microbiota and then decarboxylated to p-cresol. It is hypothesized that p-cresol may contribute to worsening the severity of ASD symptoms [44]. Urine samples will be stored at −20 °C for up to 1 week and then stored at −80 °C until processing. Urinary p-cresol levels will be determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit validated for human urine samples. Analyses will be performed according to the manufacturer’s instructions. Explanation for the choice of comparators Since there is no unequivocally proven benefit to probiotics, prebiotics, synbiotics, or any other dietary supplementation in children with ASD, placebo was chosen as the comparator. Compared to no intervention, this choice will enable complete masking and reduce the risk of bias due to knowledge of the intervention, which is a significant factor to account for in trials on ASD [45]. Rationale for treatment duration The 12-week duration of the probiotic intervention was chosen based on a review of previous clinical trials investigating probiotics in children with ASD. Reported intervention periods in the literature vary widely, ranging from 4 weeks to 6 months, and there are currently no established guidelines on the optimal treatment duration. Given this variability, a 12-week intervention was selected as a pragmatic duration that balances sufficient time to observe potential effects and to maintain good participant compliance throughout the study. Sample size The sample size was calculated based on the primary outcome (ASRS) using a web-based statistical calculator (Statulator, https://www.statulator.com) [46]. As the expected effect of probiotics on autism symptoms is unknown, we based our sample size calculation on a difference of 5 points in ASRS score. This value is sufficient to differentiate between a patient at the lower bound of the “slightly elevated” category and a patient from the “elevated” category, as well as between a patient from the lower bound of the “elevated” category and a patient from the “very elevated” category [36]. Based on the data from an RCT conducted previously in our department, we assumed a standard deviation of 8.5, which is an average of the standard deviations of ASRS scores in the study groups [10]. To achieve a power of 80% and a level of significance of 5%, the study will require a sample size of 46 participants for each group and a total of 92 patients. After increasing this number by 20% to account for potential dropouts, the total population will consist of 110 individuals. The power to detect significant differences under various scenarios of loss-to-follow-up and mean differences is presented in the Supplementary Table. Data collection At the beginning of the study, the patients will be introduced to the study protocol. After obtaining informed, written consent to participate in the study, demographic data and basic medical records will be collected. All questionnaires used in the study will be completed by the parent or caregiver. Questionnaires will be filled twice—at the beginning and at the end of the study (i.e., after 3 months of intervention). It will take between 60 and 90 min to complete all the questionnaires. Questionnaires will be paper based and distributed by researchers during face-to-face appointments at the clinic. Each participant in the study will be given an individual number. After completing the paper sheets, the data will be transferred by the researcher to an electronic database. Data analysis plan (Table 1) Table 1Study timeline Study timeline Statistical analysis Descriptive statistics will be employed to summarize the baseline characteristics of study participants. In the primary analysis, we will compare the differences in outcome measures between two groups: the intervention group receiving probiotics and the placebo group. The difference between questionnaire score changes will be calculated from T0 (initial assessment) to T1 (final assessment). Student’s t-test will be utilized to compare means of continuous variables that exhibit a normal distribution. In cases where the data are not normally distributed, the Mann–Whitney U-test will be used instead. Additionally, within-group questionnaire scores will be compared between T0 and T1 with dependent samples t-test or Wilcoxon signed-rank test for normal and non-normal data distribution, respectively. The distribution of data will be assessed with the Shapiro–Wilk test and visual inspection of the distribution histograms. All the randomized participants with available outcome data will be analyzed in the intention-to-treat (ITT) analysis, regardless of whether or not they were compliant with the study protocol. Additionally, per-protocol analysis will be performed on the compliant participants. Compliance with the placebo/probiotic ingestion will be defined as the usage of at least 75% of the intended study product doses. In case of missing outcome data, multiple imputation methods will be considered according to the methods described by Jakobsen et al. [47]. Missing data will first be assessed for extent and pattern. If the proportion of missing data is minimal (< 5%) and unlikely to be related to participant characteristics or outcomes, a complete-case analysis will be used. If missing data are more substantial or plausibly not missing completely at random, multiple imputation using chained equations will be applied to generate ≥ 50 complete datasets, with results combined using Rubin’s rules. Sensitivity analyses with extreme value scenarios will be performed to assess the robustness of findings. The primary estimand is the average treatment effect of probiotic versus placebo, measured as the between-group difference in the change of ASRS scores from T0 to T1 in the ITT population. The differences in means or medians (depending on the distribution of the data), all accompanied by a 95% confidence interval (CI) or interquartile range (IQR), respectively, will be calculated. The difference between study groups will be considered statistically significant if the p-value is less than 0.05. Additionally, a linear mixed-effects model analysis will be performed. Based on the literature, we have identified a number of covariates that may affect the primary and secondary outcomes [16, 25, 27]. The model will be adjusted for the following factors: the age of participants (children up to 10 years and adolescents from 11 years of age), sex of participants, the occurrence of gastrointestinal symptoms (none or mild and moderate or severe symptoms at baseline), significant diet changes (yes/no), new medications, dose changes of previously used medications (yes/no), and initiation of behavioral therapies (yes/no). Patients will be classified into two subgroups based on the occurrence of gastrointestinal symptoms at baseline: “NGIS”—none/mild gastrointestinal symptoms at baseline or “GIS”—moderate/severe gastrointestinal symptoms at baseline. If the participant provides an answer to any of the GSRS questions as “4” or above (4—moderate, 5—moderately severe, 6—severe, 7—very severe discomfort), then they will be classified as “GIS.” If the participant answers as 3 or below (1—no discomfort, 2—slight discomfort, 3—mild discomfort), then they will be classified as “NGIS.” Additionally, the time of assessment (T0, T1) from the same patient will be added as a random effect. Adverse events The information about the occurrence of any adverse effects resulting from the use of probiotics or placebo will be gathered from all study participants. The cumulative frequency of all adverse events, as well as the individual types of adverse events, will be compared between the groups using the χ2 test or Fisher’s exact test, as appropriate. The relative risk (RR) with a 95% confidence interval (95% CI) will be calculated. Adherence and deviation from protocol analysis Any noncompliance with the protocol, including withdrawal, loss to follow-up, or failure to ingest 75% of the planned doses of probiotic/placebo, will be documented and summed for both subgroups, and the RR with 95% CI of deviation due to exposure to the active substance will be calculated. Data management The paper copies of the case report forms (CRFs) and all study data will be securely stored in a designated locker located within the study site. Both electronic and paper versions of the CRFs will be accessible only to the researchers who are directly involved in the study (M. K., J. Ł., H. S.). Confidentiality of participants’ personal information will be maintained by ensuring that access to this information is restricted to authorized personnel only. To uphold this commitment, no personal data will be shared with the party responsible for the randomization process, study product production, statistician, or any other external entities. Study data from paper questionnaires will be pseudonymized and entered into a secure electronic spreadsheet (Microsoft Excel) stored on a password-protected computer. The hardware used for the data storage will be one of the hospital computers used in the Children’s Clinical Hospital of the Medical University of Warsaw, which is compliant with Polish and European Union regulations on personal data management and is used on a daily basis for patient care and clinical research. The account where the study data will be stored will be accessible only to the PI. Additionally, a backup copy will be made once per month on a similar password-protected computer of a senior researcher (J. Ł.). All electronic data will be collected in an “as little as necessary” manner, without names, addresses, or contact details of the participants and their families/caregivers. Data entry into the electronic database will be performed by the PI. The accuracy of data transcription will be ensured through cross-verification against the original paper forms by a senior researcher (J. Ł.). Safety and harms Throughout the study, adverse reactions will be monitored and documented. This includes changes in signs, symptoms, or health status that may or may not be causally related to the intervention or other aspects of study participation. Participation in the study will involve logistical inconveniences and time commitment for follow-up appointments, which may negatively affect daily routines and plans. Providing a urine sample for analysis may cause discomfort for the patient. The intervention product has been tested for safety and approved for use in children. The bacterial strains used in the preparation have Qualified Presumption of Safety (QPS) status established by the European Food Safety Authorities (EFSA). In Poland, probiotics are typically categorized as dietary supplements. The occurrence of severe side effects from oral probiotic intake is unlikely. Mild gastrointestinal adverse events such as abdominal pain, bloating, and vomiting are more common; however, these symptoms will be monitored using the GSRS questionnaire mentioned earlier. Patients’ parents or caregivers will be provided with the investigators’ contact details and instructed to reach out if any concerning symptoms arise. Previous clinical trials investigating probiotic interventions in children with ASD have not reported any serious adverse events, suggesting that these interventions are generally safe. Mild gastrointestinal effects, such as abdominal pain, have been occasionally observed but were transient and self-limiting [19, 21, 23, 25, 27]. If a serious adverse event is suspected, the patient’s assignment to the intervention or control group will be revealed. The event will then be analyzed for potential association with the intervention administered by the study team, along with consultation from two experts experienced in probiotic clinical trials but not affiliated with the current study. If a significant adverse event linked to probiotic usage is detected, the study will be suspended for safety analysis, and the Bioethics Committee will be promptly notified of the occurrence. Patient and public involvement statement Patients and public were not involved in the design of the study. Data monitoring and auditing A formal Data Monitoring Committee has not been established due to the low-risk nature of the probiotic intervention and no plans for interim analyses. The trial progress, data completeness, and protocol adherence will be monitored by a senior researcher (J. Ł.), who will oversee the PI’s (M. K.) work. No interim analysis will be performed in this trial due to the low-risk nature of the probiotic intervention. All primary and secondary outcome data will be analyzed after the study is completed for all participants. Although a formal Data Monitoring Committee has not been established, the Ethics Committee of the Medical University of Warsaw will be notified of any major safety concerns, protocol deviations, or amendments during the conduct of the study. Ethics and dissemination Research ethics approval The study protocol was approved by the Ethics Committee of the Medical University of Warsaw on October 9, 2023 (approval no. KB/151/2023). Informed written consent from a parent or legal guardian, along with a verbal assent by the child, will be obtained by the PI during the first visit. The consent form includes permission for the collection, storage, and use of urine samples. Protocol amendments Any protocol modification should be the object of an amendment, which will be dated and signed by all the parties involved in the development of the initial protocol. The amendment will be submitted to the appropriate ethics committees, either for approval or for information, depending on the nature and the importance of the changes to the study conditions and according to the specific regulations. Confidentiality All information collected during the study will be considered confidential and will not be disclosed. The identity of study participants, under no circumstances, will be communicated to the sponsor or to any official bodies. Only the project supervisor, the PI, and an independent statistician will be given access to the cleaned data sets. All data sets will be password-protected. To ensure confidentiality, data will be pseudonymized to avoid identifying personal participant information. Dissemination The results of this randomized controlled trial, whether positive or negative, will be published in a peer-reviewed journal. Abstracts will also be submitted to relevant national and international conferences. The trial will adhere to the Consolidated Standards of Reporting Trials (CONSORT) guidelines to ensure compliance with best practices for reporting clinical trials. Trial status This is the second version of the protocol, revised on the 27th of October 2025. The study is currently in the recruitment phase, which started on the 7th of August 2024 and is expected to be completed by the 30th of July 2026. Supplementary Information Additional file 1. Supplementary table. Power to detect a significant difference at different scenarios of loss-to-follow-up and mean difference (MD), assuming α = 0.05 and SD = 8.5. Additional file 2. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents. Authors’ contributions MK, conceptualization of the study protocol (each section), writing of the manuscript, and obtainment of the ethics committee approval. JŁ, conceptualization of the study protocol (each section) and review and edition of the manuscript. ŁK, conceptualization of the study protocol (outcome measure choice) and review of the manuscript. HS, supervision of the preparation of the protocol and review of the manuscript. All authors read and approved the final version of the protocol. Funding The Medical University of Warsaw is the study sponsor and provides the primary funding for this trial. The probiotic and placebo products will be produced and provided by Winclove Probiotics B.V. (Amsterdam, The Netherlands), free of charge. Randomization and allocation concealment will also be performed by the product manufacturer at no cost. Apart from the aspects mentioned above, Winclove Probiotics B.V. will not have a role in the conception, protocol development, design, or conduct of the study or in the analysis and interpretation of the data. Data availability The pseudonymized datasets created during this trial will be available from the PI upon a reasonable request for noncommercial research purposes only. Declarations Competing interests H. S. serves as a board member of the International Scientific Association for Probiotics and Prebiotics (ISAPP), a role that is unpaid and voluntary. She has participated as a clinical investigator, advisory board member, consultant, and speaker for several companies manufacturing probiotics, including Arla, BioGaia, Biocodex, Danone, Dicofarm, Nestlé, NNI, Nutricia, and Winclove. JŁ was the primary investigator in a trial on antibiotic-associated diarrhea in children, which assessed a probiotic manufactured by Winclove B.V. and received an unrestricted research grant from Winclove B.V. The remaining authors declare that they have no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Additional file 1. Supplementary table. Power to detect a significant difference at different scenarios of loss-to-follow-up and mean difference (MD), assuming α = 0.05 and SD = 8.5. Additional file 2. SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents. Data Availability Statement The pseudonymized datasets created during this trial will be available from the PI upon a reasonable request for noncommercial research purposes only.